Strategic pivots Orphazyme recently transitioned assets and operations through asset sales and partnerships (e.g., with KemPharm) to satisfy creditor obligations and pivot toward a commercially-driven rare disease therapeutics model. This indicates openness to collaborations, licensing, or asset-light partnerships that can be leveraged for co-development or in-licensing opportunities.

Late-stage focus With a late-stage drug pipeline and a global patient focus in neurodegenerative orphan diseases, there is a clear path for partnership discussions around late-stage clinical trials, companion diagnostics, and accelerated access programs that can accelerate time-to-market for potential buyers or co-developers.

Global footprint Established presence in Denmark, Switzerland, and the US (Chicago HQ) provides access to European and North American markets, enabling cross-border collaborations, regional licensing deals, and patient access initiatives that resonate with global biopharma buyers and contract research organizations.

Financial readiness Significant funding backing (over $262M) combined with a lean revenue base (<$1M) suggests opportunities for strategic investments, milestone-driven partnerships, or asset acquisitions that can align with buyers seeking to scale late-stage programs with committed capital.

Public market visibility Dual Nasdaq listings and ongoing corporate communications indicate transparency and investor visibility, which can be leveraged in outreach to potential strategic partners or acquirers seeking credible, well-documented collaborations in rare disease therapeutics.